MediVas partners with Pfizer on eye programs

MediVas has teamed with Pfizer to develop new therapies for eye diseases. The pact will combine MediVas work in polymers with Pfizer's compounds. No financial terms were released. "We are confident that by combining Pfizer's compounds with our best in class polymer delivery system we can help to increase patient compliance and significantly improve treatment of diseases of the eye," said Kenneth Carpenter, MediVas' president and chief executive officer.

- check out the press release on the deal
- read the UPI report on the pact

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.